



Allergic Bronchopulmonary Aspergillosis and Eosinophilic Lung Disease

Joshua A. Boyce, M.D.

Jeff and Penny Vinik Center for Allergic Disease Research
Division of Allergy and Clinical Immunology
Brigham and Women`s Hospital
Harvard Medical School

BRIGHAM HEALTH
BWH BRIGHAM AND WOMEN'S HOSPITAL
Allergy & Immunology

Jeff and Penny Vinik
CENTER FOR TRANSLATIONAL IMMUNOLOGY RESEARCH
DISCOVERY | INNOVATION | CURE

HARVARD MEDICAL SCHOOL

Disclosures

Scientific advisory boards:

- Siolta Therapeutics
- Third Harmonic Bio
- Jasper Therapeutics

Research funding:

- NIH



Paul Erlich
1854-1915

Eosinophils



- Bone marrow-derived granulocytes
- Arise from myeloid progenitor shared with basophils
- Major distribution in tissues (gut, visceral fat, generally not respiratory)
- Production in marrow increases selectively in helminth infections, allergic disease, certain tumors
- Likely involved in elimination/containment of certain helminths; potential important in brown fat maintenance and metabolic homeostasis
- Signature of allergic inflammation; frequently found in fibrotic/remodeling tissues, tumors

Eosinophil effector systems and functions

- Cationic granule proteins (MBP, ECP, EPX, EPO, CLC)- neurotoxic, epithelial damage, helminthicidal
- Cytokines (too many to mention-TGFβ is prominent)- proinflammatory, pro-fibrotic
- Lipid mediators; 5-LO (leukotrienes), 15-LO (15-HETE and products), COX (PGD_2)- bronchoconstriction, vascular leak, effector cell recruitment

Eosinophil development

- Regulated by eosinophilopoietic cytokines (IL-3, GM-CSF, IL-5*); produced mainly by T cells
- Receptors composed of ligand-specific α subunits and a shared β subunit (eosinophils, but not neutrophils or monocytes, express IL-5Rα)
- Overlapping functions, but different cellular targets (IL-3, GM-CSF act on multiple lineages; only IL-5 is selective for eosinophils)
- All three sustain survival, augment effector functions
- IL-5 is an eosinophil-selective terminal differentiation factor and a mobilization factor from marrow
- Eosinophil migration to tissues requires cooperation between IL-5 plus CCR3-binding chemokines (eotaxins 1, 2, and 3; MCP3, RANTES)

*Clutterbunk et al., Blood 1989

Sustained reduction in blood eosinophil counts in patients with hypereosinophilic syndrome (HES) in response to anti-IL-5 (mepolizumab)



Mepolizumab, Reslizumab (anti-IL5)
Benrilizumab (anti-IL-5Rα)

Plotz SG, NEJM 2003

Eosinophil-associated disease processes

- Helminth infection
- Severe “type 2 high” asthma (esp. AERD)
- Hypersensitivity reactions (e.g., DRESS)
- Tumors (lymphomas, esp. Hodgkin's and cutaneous T cell lymphoma)
- Organ-specific diseases (eosinophilic lung disease, GI disease, fasciitis, myositis, cellulitis)
- Systemic mastocytosis (15% have eosinophilia)
- Hypereosinophilic syndrome(s)

Eosinophilic lung diseases

Asthma-associated

- Allergic bronchopulmonary aspergillosis (ABPA)
- Chronic eosinophilic pneumonia (CEP)
- Eosinophilic granulomatosis and polyangiitis (EGPA, formerly Churg-Strauss syndrome)

Non-asthma-associated

- Acute eosinophilic pneumonia (AEP)
- Simple pulmonary eosinophilia (Loeffler's)
- Tropical eosinophilia (filariasis)

*Note: pulmonary eosinophilia may occur as a secondary finding in numerous systemic autoimmune, infectious and malignant diseases

Illustrative case 1

17-year-old male with type 1 diabetes, nut allergy and longstanding mild asthma (albuterol only) presents for evaluation of worsening asthma control

- 6-month history of worsening symptoms; wheeze, dyspnea, productive cough (brown sputum, occasional blood tinge)
- Prompt improvement with oral steroids but rapid recrudescence with cessation
- Denies travel, fevers, night sweats, weight loss
- Meds: Insulin, albuterol PRN (use of 1 cannister/month)

Illustrative case 1

Exam:

- Alert, oriented, NAD
- Vital signs unremarkable, Sa02 96%
- Boggy, edematous turbinates, no polyps

- Diffuse wheezing, fair air entry

- No clubbing

Illustrative case 1

Labs:

- CBC: Hct 45.7, WBC 6,270 (15% eos, TEC 940)
- IgE: 36,700
- Aspergillus SPT; 22 mm wheal, 45 mm flare
- A. fumigatus precipitins; positive
- *CFTR* mutations; none



FVC = 3.22 L (74% of pred)
FEV1 = 1.36 L (33% of pred)

Increases of 9 and 46% after albuterol

CXR-Case 1



CT-Case 1



Bronchial cast- ABPA



Silver stain, bronchial cast



ABPA

(Rosenberg-Patterson Criteria)

Major (6 or more are definitive):

- Asthma
- Positive immediate skin test to *Aspergillus*
- Total IgE >1000
- Central bronchiectasis
- Fleeting infiltrates
- Blood eosinophilia ≥ 1000 cells/μl
- Serum precipitins

*Obligate features

Minor (supportive):

- Expectoration of brownish plugs
- Positive sputum culture for *Aspergillus*
- Late (Arthus) reaction to *Aspergillus* skin test

New proposed criteria (Asano, et al. JACI 2020)

1. Current or previous history of asthma or asthmatic symptoms
2. Peripheral blood eosinophilia (>_500 cells/mm3)
3. Elevated total serum IgE levels (>_417 IU/mL)
4. Immediate cutaneous hypersensitivity or specific IgE for filamentous fungi
5. Presence of precipitins or specific IgG for filamentous fungi
6. Filamentous fungal growth in sputum cultures or bronchial lavage fluid
7. Presence of fungal hyphae in bronchial mucus plugs
8. Central bronchiectasis on CT
9. Presence of mucus plugs in central bronchi, based on CT/bronchoscopy or mucus plug expectoration history
10. High attenuation mucus in the bronchi on CT

(Filamentous fungi in criteria 4 to 6 should be identical. Patients that meet 6 or more of these criteria are diagnosed with ABPM)

ABPA

Predisposing factors:

- Pre-existing asthma or cystic fibrosis
- Heterozygous CFTR mutants maty be at increased risk
- HLA-DR2 (DRB1*1503) increases risk; HLA-DQ2 protects
- *SPA-2* variants correlate with severity
- *IL10* and *IL4RA* variants correlate with incidence

ABPA

Treatment:

- Systemic glucocorticoids
- Itraconazole (steroid-sparing in several studies)
- Omalizumab (several case reports; no RCT)
- Multiple case reports of improvement on mepolizumab
- RCTs ongoing for dupilumab (anti-IL4Rα), benralizimab (anti-IL-5Rα)

Illustrative case 1

Follow-up:

- Clinically improved after prolonged course (6 weeks) of oral steroids but glycemic control problematic
- Nasal polyp developed once off prednisone
- IgE fell to 16,300 from 36,700
- Eosinophilia remains <100 on 7.5mg daily prednisone, Symbicort, montelukast
- Lost to follow up after 2 years



FVC = 4.59 L (98% of pred)
FEV1 = 2.78 L (69% of pred)

Illustrative case 2

29-year-old male with longstanding asthma

- 3-month history of productive cough, wheeze, dyspnea- no improvement with antibiotics
- Recent 10-pound weight loss, night sweats
- Exam- Wheezing and dense crackles on lung auscultation, no nasal polyps, no rash or extrapulmonary signs
- Lung function: FEV1 76% of predicted, FVC 65% of predicted; increases of 8 and 12%, respectively, with bronchodilator
- Labs: significant eosinophilia (WBC 6,700, 27.5% eosinophils-TEC = 1842); Total IgE 127, skin testing positive for *Aspergillus* but precipitins

CXR-Case 2



CT-Case 2



Lung biopsy-Case 2



Chronic Eosinophilic Pneumonia (CEP)

- First reported in 1968 (Carrington, NEJM)
- Usually middle aged asthmatics
- Indolent, slowly progressive
- Blood eosinophilia common but not uniform
- BAL fluid eosinophilia
- Alveolar filling with eosinophils, macrophages
- Fibrosis with longstanding disease
- Steroid-responsive, high rate of recurrence
- Mepolizumab efficacious in a “real world” study (Brenard E., et al. Lung 2020;198:355-360)-no RCT published

Illustrative Case 3

34-year-old male with longstanding history of asthma and allergic rhinitis presents with worsening dyspnea, cough, one episode of mild hemoptysis

- Worsening sinus congestion, epistaxis
- Recent nocturnal fevers, numbness of left hand
- Abdominal pain and rash (nodules)
- Exam: palpable nodules on lower extremities, diffuse wheezing, nasal polyps
- CBC: HCT 29, WBC 8600, 15% eos (AEC 1290), IgE 675, ANCA negative, CRP 36

Illustrative Case 3

No “classical” radiographic features (nodules, infiltrates, sometimes peripheral)





Skin biopsy:

Necrotizing small vessel vasculitis with extravasated eosinophils



EGPA diagnostic criteria

American College of Rheumatology classification criteria (1990) ‡
Asthma
Eosinophilia >10% of total WBC
Neuropathy
Pulmonary infiltrates nonfixed
Paranasal sinus abnormalities
Extravascular eosinophils
Revised Chapel Hill Consensus Conference Nomenclature of Vasculitides (2012)
Eosinophil-rich and necrotizing granulomatous inflammation often involving the respiratory tract, and necrotizing vasculitis predominantly affecting small-to-medium vessels, and associated with asthma and eosinophils. ANCA is more frequent when glomerulonephritis is present.

Mepolizumab for EGPA (FDA approved in 2019)





*Benralizumab (anti-IL-5Rα) non-inferior to mepolizumab

Weschler M, NEJM 2019
Weschler M, NEJM 2024*

CONCLUSIONS

Eosinophilic lung disorders

- Asthma-associated; ABPA, CEP, EGPA
- Not asthma-associated; AEP, Loeffler's, tropical eosinophilia
- Suspect diagnoses in patients with loss of asthma control, eosinophilia, or (in the case of EGPA) prominent extrapulmonary symptoms
- Eosinophilia is the common thread; associated lab, radiographic, and clinical features help distinguish
- Anti-IL-5 efficacious for EGPA; await studies in other disorders